Policy & Regulation
Zealand Pharma and Boehringer Ingelheim to conduct Phase 2 trials of BI 456906 in obesity and NASH
13 April 2021 -

Danish biotechnology company Zealand Pharma A/S (NASDAQ:ZEAL) (CPH:ZEAL) and German pharmaceutical company Boehringer Ingelheim announced on Tuesday the launch of two Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults who are overweight or obese and for adults with non-alcoholic steatohepatitis (NASH).

It's hoped that the once-weekly therapy may offer additional benefits for both chronic weight management and NASH improvement and prevention of the progression to cirrhosis compared to currently available treatments with mono GLP-1 agonist compounds.

The compound is also being investigated in an ongoing Phase 2 study in people with type 2 diabetes mellitus.

Boehringer Ingelheim and Zealand have a longstanding partnership, bringing together Zealand's expertise in the discovery of innovative peptide-based medicines with Boehringer Ingelheim's expertise in the research and development of novel medicines for cardiometabolic diseases.



Related Headlines